STLN
Starling Oncology, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
Starling Oncology, Inc.
Expected move
InputsNext report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
No other changes.
No other changes.
No peers for Starling Oncology, Inc. yet.
No peers for Starling Oncology, Inc. yet.
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Annual filing, not covered
Not parsed · ties from counterparty filings
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Annual filing, not covered
Not parsed · ties from counterparty filings
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants for cancer patients. The company was founded in 2007 and is based in Cerritos, California.
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants for cancer patients. The company was founded in 2007 and is based in Cerritos, California.
Tall tick = annual report · Source: EDGAR
Starling Oncology, Inc.
6.55
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $25.8M | 11.03% | +7.54% |
| Deerfield | $18.2M | 7.80% | 0.00% |
| Vanguardindex-like | $17.7M | 7.58% | −6.08% |
| Josh Arnold Investment Consultant | $13.4M | 5.72% | 0.00% |
| Geodeindex-like | $10.3M | 4.41% | +8.09% |
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $25.8M | 11.03% | +7.54% |
| Deerfield | $18.2M | 7.80% | 0.00% |
| Vanguardindex-like | $17.7M | 7.58% | −6.08% |
| Josh Arnold Investment Consultant | $13.4M | 5.72% | 0.00% |
| Geodeindex-like | $10.3M | 4.41% | +8.09% |
Expected move
Inputsspot 6.53exp Nov 20ATM strike 7ATM straddle 1.27IV 95%